ThromboGenics NV has entered into an agreement with Alcon, a division of Novartis, for the commercialization of ocriplasmin in all markets outside the U.S. ThromboGenics will focus on commercializing ocriplasmin in the U.S., where it plans to build its commercial and medical organization to support the anticipated product launch. The two companies will also work together and share costs to develop new clinical applications of the product to introduce in their respective territories. ThromboGeni...